Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abreva Shortened Healing Time, Duration Of Cold Sores Stressed In Promos

This article was originally published in The Tan Sheet

Executive Summary

SmithKline Beecham's Abreva, now hitting shelves in food, drug and mass outlets, is the first OTC indicated for shortening the healing time and duration of symptoms related to cold sores and fever blisters.
Advertisement

Related Content

Carmex Cold Sore Treatment Claims Exceed Monograph Limit In NAD Review
Carmex Cold Sore Treatment Claims Exceed Monograph Limit In NAD Review
Carmex Cold Sore Treatment Claims Exceed Monograph Limit In NAD Review
GSK Abreva Performance Claims Affirmed By NAD, Leave Novartis Sore
GSK Abreva Performance Claims Affirmed By NAD, Leave Novartis Sore
GSK Abreva Performance Claims Affirmed By NAD, Leave Novartis Sore
GlaxoSmithKline Abreva $10 Mil. Sales Help Offset Smoking Cessation Woes
Direct-To-OTC Approvals, Line Extensions Replace Switches In 2000
Avanir Abreva Cold Sore/Fever Blister Cream Approved By FDA
Avanir Abreva Cold Sore/Fever Blister Cream Approved By FDA

Topics

Advertisement
UsernamePublicRestriction

Register

PS091948

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel